Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07748156 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SNC116 Therapy for Refractory Systemic Lupus Erythematosus

StatusNot Yet Recruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary endpoint(s) modified Start date: Aug 2026 to Oct 2026 · Eligibility criteria expanded, about 50 words · Secondary endpoints: 9 to 5 · 2 more Show 5 more changesShow less
    • Start date: Aug 2026 to Oct 2026
    • Eligibility criteria expanded, about 50 words
    • Secondary endpoints: 9 to 5
    • Study description shortened, about 127 words
    • Site contact updated
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to evaluate the safety and tolerability of SNC116 in treating patients with systemic lupus erythematosus.
Trial Details
NCT Number NCT07748156
Lead Sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Collaborators: Shanghai Simnova Biotechnology Co.,Ltd.
Conditions Systemic Lupus Erythematosus
Enrollment 28 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov